Verzenio contains the active ingredient abemaciclib, an oral targeted therapy classified as a cyclin-dependent kinase (CDK) 4 and 6 inhibitor. It is used in the treatment of hormone receptor (HR)-positive, HER2-negative breast cancer in various settings, including early-stage and advanced or metastatic disease. Verzenio may be used alone or in combination with endocrine therapies such as aromatase inhibitors or fulvestrant, depending on the patient's clinical situation.

Abemaciclib works by selectively blocking CDK4 and CDK6, enzymes that regulate cell cycle progression. By inhibiting these proteins, Verzenio helps prevent cancer cells from dividing and proliferating, which can slow tumor growth and improve treatment outcomes.

The medication is administered orally and is typically taken twice daily, with or without food. Treatment duration varies based on the indication, disease stage, and individual patient response. Regular monitoring of blood counts, liver function, and other clinical parameters is recommended during therapy.

Clinical studies have demonstrated that Verzenio can significantly improve progression-free survival and, in certain patient populations, overall survival when used as part of an appropriate treatment regimen. It has become an important treatment option in the management of HR-positive, HER2-negative breast cancer.

Common side effects may include diarrhea, fatigue, nausea, decreased appetite, abdominal pain, infections, anemia, and low white blood cell counts. Serious adverse reactions can include severe diarrhea, blood clots, liver toxicity, and lung inflammation. Patients should be closely monitored by their healthcare provider throughout treatment.